Research Progress on Pathological Mechanism of Seasonal Allergic Rhinitis and its Chinese Medicine Therapeutic Mechanism

Abstract

Abstract: Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa caused by exposure of an atopic individual to an allergen. As a member of the IL-1 family，IL-33 plays an important role in allergic rhinitis by binding to its receptor ST2 after activation of allergens such as pollen. This article reviews the research progress of IL-33 and its receptor ST2 in AR， and analyzed the mechanism of IL-33/ST2 pathway used of traditional Chinese medicine compound in allergic diseases.

Key words: font-size:medium, ">Interleukin-33；ST2；Rhinallergosis；Mechanism of action

CLC Number:

ZHANGWei, WANG Tian, CHU Xiao-yi, WANG Li-li, TANG Li. Research Progress on Pathological Mechanism of Seasonal Allergic Rhinitis and its Chinese Medicine Therapeutic Mechanism[J]. CHINESE JOURNAL OF DRUG EVALUATION, 2022, 39(5): 399-405.

References

[1]中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组，中华医学会耳鼻咽喉头颈外科学分会鼻科学组. 中国变应性鼻炎诊断和治疗指南(2022年，修订版) %J 中华耳鼻咽喉头颈外科杂志[J]. 2022， 57(2)： 106-129.
     [2]Wise SK， Lin SY， Toskala E， et al. International Consensus Statement on Allergy and Rhinology： Allergic Rhinitis[J]. Int Forum Allergy Rhinol， 2018， 8(2)： 108-352.
     [3]Cheng L， Chen J， Fu Q， et al. Chinese Society of Allergy Guidelines for Diagnosis and Treatment of Allergic Rhinitis[J]. Allergy Asthma Immunol Res， 2018， 10(4)： 300-353.
     [4]Brozek JL， Bousquet J， Agache I， et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision[J]. J Allergy Clin Immunol， 2017， 140(4)： 950-958.
     [5]Bousquet PJ， Leynaert B， Neukiech F， et al. Geographical distribution of atopic rhinitis in the European Community Respiratory Health Survey I[J]. Allergy， 2008， 63(10)： 1301-1309.
     [6]Asher M I， Stewart AW， Mallol J， et al. Which population level environmental factors are associated with asthma， rhinoconjunctivitis and eczema? Review of the ecological analyses of ISAAC Phase One[J]. Respir Res， 2010， 11(1)： 8.
     [7]Yamada T， Saito H， Fujieda S. Present state of Japanese cedar pollinosis： the national affliction[J]. J Allergy Clin Immunol， 2014， 133(3)： 632-639.e635.
     [8]Wang XY， Ma TT， Wang XY， et al. Prevalence of pollen-induced allergic rhinitis with high pollen exposure in grasslands of northern China[J]. Allergy， 2018， 73(6)： 1232-1243.
     [9]Asher MI， Montefort S， BJRKSTéN B， et al. Worldwide time trends in the prevalence of symptoms of asthma， allergic rhinoconjunctivitis， and eczema in childhood： ISAAC Phases One and Three repeat multicountry cross-sectional surveys[J]. Lancet， 2006， 368(9537)： 733-743.
     [10]Bousquet J， Anto JM， Bachert C， et al. Allergic rhinitis[J]. Nat Rev Dis Primers， 2020， 6(1)： 95.
     [11]Hammad H， Lambercht BN. Barrier Epithelial Cells and the Control of Type 2 Immunity[J]. Immunity， 2015， 43(1)： 29-40.
     [12]Erkara IP， Cingi C， Ayranci U， et al. Skin prick test reactivity in allergic rhinitis patients to airborne pollens[J]. Environ Monit Assess， 2009， 151(1-4)： 401-412.
     [13]Cayrol C， Duval A， SchmittP， et al. Environmental allergens induce allergic inflammation through proteolytic maturation of IL-33[J]. Nat Immunol， 2018， 19(4)： 375-385.
     [14]Roan F， Obata-Ninomiya K， Ziegler SF. Epithelial cell-derived cytokines： more than just signaling the alarm[J]. J Clin Invest， 2019， 129(4)： 1441-1451.
     [15]ConnellJ T. Quantitative intranasal pollen challenges. 3. The priming effect in allergic rhinitis[J]. J Allergy， 1969， 43(1)： 33-44.
     [16]Sakashita M， Yoshimotot， Hirota T， et al. Association of serum interleukin-33 level and the interleukin-33 genetic variant with Japanese cedar pollinosis[J]. Clin Exp Allergy， 2008， 38(12)： 1875-1881.
     [17]Wen W， Yang F， Shen X， et al. Regulatory Role of Zinc in Allergic Rhinitis through the IL-33/ST2 Pathway[J]. J Healthc Eng， 2022， 2022： 3718317.
     [18]GLüCK J， Rymarczyk B， Jura-SZOTYS E， et al. Serum levels of interleukin 33 and its receptor ST2 in patients treated with subcutaneous allergen immunotherapy in intermittent allergic rhinitis[J]. Cent Eur J Immunol， 2019， 44(2)： 214-217.
     [19]Asaka D， Yoshkawa M， Nakayama T， et al. Elevated levels of interleukin-33 in the nasal secretions of patients with allergic rhinitis[J]. Int Arch Allergy Immunol， 2012， 158 Suppl 1： 47-50.
     [20]Cayrol C， Girard J P. Interleukin-33 (IL-33)： A nuclear cytokine from the IL-1 family[J]. Immunol Rev， 2018， 281(1)： 154-168.
     [21]Haenuki Y， Matsushita K， Futatsugi-Yumikura S， et al. A critical role of IL-33 in experimental allergic rhinitis[J]. J Allergy Clin Immunol， 2012， 130(1)： 184-194.e111.
     [22]Onda H， Kasuya H， Takakura K， et al. Identification of genes differentially expressed in canine vasospastic cerebral arteries after subarachnoid hemorrhage[J]. J Cereb Blood Flow Metab， 1999， 19(11)： 1279-1288.
     [23]Baekkevold E S， RoussgNé M， Yamanaka T， et al. Molecular characterization of NF-HEV， a nuclear factor preferentially expressed in human high endothelial venules[J]. Am J Pathol， 2003， 163(1)： 69-79.
     [24]Schmitz J， Owyang A， Oldham E， et al. IL-33， an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines[J]. Immunity， 2005， 23(5)： 479-490.
     [25]Rostan O， Arshad MI， Piquet-Pellorce C， et al. Crucial and diverse role of the interleukin-33/ST2 axis in infectious diseases[J]. Infect Immun， 2015， 83(5)： 1738-1748.
     [26]Carriere V， Roussel L， Ortega N， et al. IL-33， the IL-1-like cytokine ligand for ST2 receptor， is a chromatin-associated nuclear factor in vivo[J]. Proc Natl Acad Sci U S A， 2007， 104(1)： 282-287.
     [27]Di Salvo E， Venture-Spagnolo E， Casciord M， et al. IL-33/IL-31 Axis： A Potential Inflammatory Pathway[J]. Mediators Inflamm， 2018， 2018： 3858032.
     [28]Garlanda C， Dinarello CA， Mantovani A. The interleukin-1 family： back to the future[J]. Immunity， 2013， 39(6)： 1003-1018.
     [29]Murdaca G， Greco M， Tonacci A， et al. IL-33/IL-31 Axis in Immune-Mediated and Allergic Diseases[J]. Int J Mol Sci， 2019， 20(23).
     [30]Martin S J. Cell death and inflammation： the case for IL-1 family cytokines as the canonical DAMPs of the immune system[J]. Febs j， 2016， 283(14)： 2599-2615.
     [31]Cayrol C， Girard J P. IL-33： an alarmin cytokine with crucial roles in innate immunity， inflammation and allergy[J]. Curr Opin Immunol， 2014， 31： 31-37.
     [32]Cayrol C. IL-33， an Alarmin of the IL-1 Family Involved in Allergic and Non Allergic Inflammation： Focus on the Mechanisms of Regulation of Its Activity[J]. Cells， 2021， 11(1).
     [33]Han X， Krempski J W， Nadeau K. Advances and novel developments in mechanisms of allergic inflammation[J]. Allergy， 2020， 75(12)： 3100-3111.
     [34]Lefranais E， Duval A， Mirey E， et al. Central domain of IL-33 is cleaved by mast cell proteases for potent activation of group-2 innate lymphoid cells[J]. Proc Natl Acad Sci U S A， 2014， 111(43)： 15502-15507.
     [35]Lefranais E， Roga S， Gautier V， et al. IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G[J]. Proc Natl Acad Sci U S A， 2012， 109(5)： 1673-1678.
     [36]Gilles-stein S， Beck I， Chaker A， et al. Pollen derived low molecular compounds enhance the human allergen specific immune response in vivo[J]. Clin Exp Allergy， 2016， 46(10)： 1355-1365.
     [37]Zhu K， Xia C， Chen J， et al. Serum Soluble ST2 Correlated with Symptom Severity and Clinical Response of Sublingual Immunotherapy for House Dust Mite-Induced Allergic Rhinitis Patients[J]. Mediators Inflamm， 2021， 2021： 5576596.
     [38]Pusceddu I， Dieplinger B， Mueller T. ST2 and the ST2/IL-33 signalling pathway-biochemistry and pathophysiology in animal models and humans[J]. Clin Chim Acta， 2019， 495： 493-500.
     [39]Fattori V， Hohmann MSN， Rossaneis AC， et al. Targeting IL-33/ST2 signaling： regulation of immune function and analgesia[J]. Expert Opin Ther Targets， 2017， 21(12)： 1141-1152.
     [40]Liu X， Hammel M， He Y， et al. Structural insights into the interaction of IL-33 with its receptors[J]. Proc Natl Acad Sci U S A， 2013， 110(37)： 14918-14923.
     [41]Lingel A， Weis T M， Niebuhr M， et al. Structure of IL-33 and its interaction with the ST2 and IL-1RAcP receptors--insight into heterotrimeric IL-1 signaling complexes[J]. Structure， 2009， 17(10)： 1398-1410.
     [42]Günther S， Deredge D， Bowers A L， et al. IL-1 Family Cytokines Use Distinct Molecular Mechanisms to Signal through Their Shared Co-receptor[J]. Immunity， 2017， 47(3)： 510-523.e514.
     [43]Griesenauer B， Paczesny S. The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases[J]. Front Immunol， 2017， 8： 475.
     [44]De La Fuente M， Macdonald TT， Hermoso MA. The IL-33/ST2 axis： Role in health and disease[J]. Cytokine Growth Factor Rev， 2015， 26(6)： 615-623.
     [45]Drakde LY， Kita H. IL-33： biological properties， functions， and roles in airway disease[J]. Immunol Rev， 2017， 278(1)： 173-184.
     [46]Iinuma T， Okamoto Y， Morimoto Y， et al. Pathogenicity of memory Th2 cells is linked to stage of allergic rhinitis[J]. Allergy， 2018， 73(2)： 479-489.
     [47]Eissmann MF， Dijkstra C， Wouters MA， et al. Interleukin 33 Signaling Restrains Sporadic Colon Cancer in an Interferon-γ-Dependent Manner[J]. Cancer Immunol Res， 2018， 6(4)： 409-421.
     [48]Perales-puchaltT A， Svoronos N， Villarreal DO， et al. IL-33 delays metastatic peritoneal cancer progression inducing an allergic microenvironment[J]. Oncoimmunology， 2019， 8(1)： e1515058.
     [49]Melichar B， Freedman R S. Immunology of the peritoneal cavity： relevance for host-tumor relation[J]. Int J Gynecol Cancer， 2002， 12(1)： 3-17.
     [50]Yang Y， Liu H， Zhang H， et al. ST2/IL-33-Dependent Microglial Response Limits Acute Ischemic Brain Injury[J]. J Neurosci， 2017， 37(18)： 4692-4704.
     [51]Liu X， Liu J， Zhao S， et al. Interleukin-4 Is Essential for Microglia/Macrophage M2 Polarization and Long-Term Recovery After Cerebral Ischemia[J]. Stroke， 2016， 47(2)： 498-504.
     [52]Xiong X， Xu L， Wei L， et al. IL-4 Is Required for Sex Differences in Vulnerability to Focal Ischemia in Mice[J]. Stroke， 2015， 46(8)： 2271-2276.
     [53]Liew FY， Girard JP， Turnquist HR. Interleukin-33 in health and disease[J]. Nat Rev Immunol， 2016， 16(11)： 676-689.
     [54]Pointner L， Bethanis A， Thaler M， et al. Initiating pollen sensitization-complex source， complex mechanisms[J]. Clin Transl Allergy， 2020， 10： 36.
     [55]Moussion C， Ortega N， Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo： a novel 'alarmin'?[J]. PLoS One， 2008， 3(10)： e3331.
     [56]Corren J， Ziegler SF. TSLP： from allergy to cancer[J]. Nat Immunol， 2019， 20(12)： 1603-1609.
     [57]Xu D， Chan WL， Leung B P， et al. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells[J]. J Exp Med， 1998， 187(5)： 787-794.
     [58]Trajkvoic V， Sweet MJ， Xu D. T1/ST2--an IL-1 receptor-like modulator of immune responses[J]. Cytokine Growth Factor Rev， 2004， 15(2-3)： 87-95.
     [59]Jeon YJ， Gil CH， Won J， et al. Symbiotic microbiome Staphylococcus aureus from human nasal mucus modulates IL-33-mediated type 2 immune responses in allergic nasal mucosa[J]. BMC Microbiol， 2020， 20(1)： 301.
     [60]Amin K. The role of mast cells in allergic inflammation[J]. Respir Med， 2012， 106(1)： 9-14.
     [61]Nian JB， Zeng M， Zheng J， et al. Epithelial cells expressed IL-33 to promote degranulation of mast cells through inhibition on ST2/PI3K/mTOR-mediated autophagy in allergic rhinitis[J]. Cell Cycle， 2020， 19(10)： 1132-1142.
     [62]Huang R， Mao W， Wang G， et al. Synergistic relationship between TSLP and IL-33/ST2 signaling pathways in allergic rhinitis and the effects of hypoxia[J]. Int Forum Allergy Rhinol， 2020， 10(4)： 511-520.
     [63]Saluja R， Hawro T， Eberle J， et al. Interleukin-33 promotes the proliferation of mouse mast cells through ST2/MyD88 and p38 MAPK-dependent and Kit-independent pathways[J]. J Biol Regul Homeost Agents， 2014， 28(4)： 575-585.
     [64]Ryu WI， Lee H， Kim JH， et al. IL-33 induces Egr-1-dependent TSLP expression via the MAPK pathways in human keratinocytes[J]. Exp Dermatol， 2015， 24(11)： 857-863.
     [65]Liu S， Mi WL， Li Q， et al. Spinal IL-33/ST2 Signaling Contributes to Neuropathic Pain via Neuronal CaMKII-CREB and Astroglial JAK2-STAT3 Cascades in Mice[J]. Anesthesiology， 2015， 123(5)： 1154-1169.
     [66]Li YQ， Zhong Y， Xiao XP， et al. IL-33/ST2 axis promotes the inflammatory response of nasal mucosal epithelial cells through inducing the ERK1/2 pathway[J]. Innate Immun， 2020， 26(6)： 505-513.
     [67]Liu HC， Liao Y， Liu CQ. miR-487b mitigates allergic rhinitis through inhibition of the IL-33/ST2 signaling pathway[J]. Eur Rev Med Pharmacol Sci， 2018， 22(23)： 8076-8083.
     [68]林玛丽，蔡旭龙，李秀洪，等. IL-33及其受体ST2与支气管哮喘相关性的研究进展[J]. 安徽医学， 2018， 39(09)： 1155-1157.
     [69]Magat JM， Thomas JL， Dumouchel JP， et al. Endogenous IL-33 and Its Autoamplification of IL-33/ST2 Pathway Play an Important Role in Asthma[J]. J Immunol， 2020， 204(6)： 1592-1597.
     [70]李鑫，刘圆圆，张才擎. 白介素-33在支气管哮喘发病机制中的作用[J]. 中华临床医师杂志(电子版)， 2019， 13(5)： 389-392.
     [71]El-husseini ZW， Gosens R， Dekker F， et al. The genetics of asthma and the promise of genomics-guided drug target discovery[J]. Lancet Respir Med， 2020， 8(10)： 1045-1056.
     [72]Smith D， Helgason H， Sulem P， et al. A rare IL33 loss-of-function mutation reduces blood eosinophil counts and protects from asthma[J]. PLoS Genet， 2017， 13(3)： e1006659.
     [73]SANOFI. Sanofi and Regeneron announce positive topline Phase 2 results for IL-33 antibody in asthma [Z]. 2019
     [74]Wu H， Yang S， Wu X， et al. Interleukin-33/ST2 signaling promotes production of interleukin-6 and interleukin-8 in systemic inflammation in cigarette smoke-induced chronic obstructive pulmonary disease mice[J]. Biochem Biophys Res Commun， 2014， 450(1)： 110-116.
     [75]Shang J， Zhao J， Wu X， et al. Interleukin-33 promotes inflammatory cytokine production in chronic airway inflammation[J]. Biochem Cell Biol， 2015， 93(4)： 359-366.
     [76]Zaini A， Fulford TS， Grumont RJ， et al. c-Rel Is Required for IL-33-Dependent Activation of ILC2s[J]. Front Immunol， 2021， 12： 667922.
     [77]Soyfoo MS， Nicaise C. Pathophysiologic role of Interleukin-33/ST2 in Sjgren′s syndrome[J]. Autoimmun Rev， 2021， 20(3)： 102756.
     [78]张嘉骏，贺雪成，刘沁东，等. 小青龙汤对变应性鼻炎小鼠IL-33/ST2信号通路的影响[J]. 中国实验方剂学杂志，2022， 28(14)： 13-19.
     [79]刘翠霞. 温肺饮对慢性支气管炎急性发作患者血清IL-2、IL-33、PCT水平的影响[J]. 陕西中医，2018， 39(3)： 304-306.
     [80]刘鑫，刘姿琴，杨苏琴，等. 柴朴汤对肝郁型哮喘小鼠CADM1、MAL、IL-33、TSLP表达的影响[J]. 中南医学科学杂志，2021， 49(5)： 502-505.
     [81]杨斌，李燕，林美娇，等. 加味芎蝎散对咳嗽变异性哮喘大鼠气道黏膜上皮连接相关蛋白表达的影响[J]. 中国中医急症，2019， 28(9)： 1513-1517.
     [82]朴香，虞坚尔，薛征，等. 基于IL-33-ST2信号通路对平喘化痰方干预哮喘小鼠机制的研究[J]. 时珍国医国药，2020， 31(11)： 2605-2609.
     [83]Huang W， Song Y， Wang L. Wenshen decoction suppresses inflammation in IL-33-induced asthma murine model via inhibiting ILC2 activation[J]. Ann Transl Med， 2019， 7(20)： 570.
     [84]Jeon WY， Shin HK， Shin IS， et al. Soshiho-tang water extract inhibits ovalbumin-induced airway inflammation via the regulation of heme oxygenase-1[J]. BMC Complement Altern Med， 2015， 15： 329.
     [85]王东明，丁佩军，马欣， et al. 清热祛湿方对丝聚合基因缺乏特应性皮炎样模型小鼠IL-33/ST2信号通路的影响[J]. 中华中医药杂志，2020， 35(3)： 1493-1497.
     [86]Chen M， Ding P， Yang L， et al. Evaluation of Anti-Inflammatory Activities of Qingre-Qushi Recipe (QRQS) against Atopic Dermatitis： Potential Mechanism of Inhibition of IL-33/ST2 Signal Transduction[J]. Evid Based Complement Alternat Med， 2017， 2017： 2489842.
     [87]张晓桐，魏芹，蔡琛，等. 当归饮子抑制IL-33介导的肥大细胞脱颗粒缓解荨麻疹样病变小鼠过敏反应的效应机制[J]. 中华中医药学刊，2021， 39(11)： 144-148，268-270.